Clincosm LogoSign in Get a demo

relapsing multiple sclerosis (rms)

Showing 1 - 7 of 7
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsing Multiple Sclerosis (RMS) Trial in United States (Ofatumumab, mRNA COVID-19 vaccine, interferon or glatiramer acetate)

Recruiting
  • Relapsing Multiple Sclerosis (RMS)
  • Phoenix, Arizona
  • +3 more
Jul 20, 2022

Assess Adherence to Treatment for Patients With RMS (MAIN-MS)

Completed
  • Relapsing Multiple Sclerosis (RMS)
  • Rebif (Interferon beta-1a)
  • Alger, Algeria
  • +40 more
Mar 22, 2022

Relapsing Multiple Sclerosis (RMS) Trial in Worldwide (Ublituximab)

Enrolling by invitation
  • Relapsing Multiple Sclerosis (RMS)
  • Ublituximab
  • Pasadena, California
  • +84 more
Mar 22, 2022

Relapsing Multiple Sclerosis (RMS) Trial in Germany, Poland (Cladribine, Placebo, Microgynon®)

Active, not recruiting
  • Relapsing Multiple Sclerosis (RMS)
  • Bochum, Germany
  • +6 more
Feb 8, 2022

Relapsing Multiple Sclerosis (RMS) Trial in China (Fingolimod 0.5mg)

Recruiting
  • Relapsing Multiple Sclerosis (RMS)
  • Fingolimod 0.5mg
  • Beijing, Beijing, China
  • +12 more
Feb 3, 2022

Relapsing Multiple Sclerosis (RMS) Trial in United States (Ublituximab, Teriflunomide, Oral Placebo)

Completed
Has Results
  • Relapsing Multiple Sclerosis (RMS)
  • Ublituximab
  • +3 more
  • Phoenix, Arizona
  • +12 more
Nov 11, 2021

Relapsing Multiple Sclerosis (RMS) Trial in United States (Ublituximab, Teriflunomide, Oral Placebo)

Completed
Has Results
  • Relapsing Multiple Sclerosis (RMS)
  • Ublituximab
  • +3 more
  • Carlsbad, California
  • +13 more
Nov 5, 2021